Publication
2023
- Loke, J. et al. 2023. Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS. Blood Advances 7(14), pp. 3666-3676. (10.1182/bloodadvances.2022009493)
- Ljungman, P. et al. 2023. Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry. Frontiers in Immunology 14, article number: 1125824. (10.3389/fimmu.2023.1125824)
2022
- Drozd-Sokołowska, J. et al. 2022. Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation-study on behalf of CMWP of the EBMT. Bone Marrow Transplantation 57, pp. 633-640. (10.1038/s41409-022-01592-y)
- Hashem, H. et al. 2022. Correction to: Hematopoietic cell transplantation cures adenosine deaminase 2 deficiency: report on 30 patients. Journal of Clinical Immunology (10.1007/s10875-022-01280-y)
- Gutiérrez-García, G. et al. 2022. Long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high-risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party-EBMT. British Journal of Haematology 196(4), pp. 1018-1030. (10.1111/bjh.17939)
2021
- Griffiths, J. S. et al. 2021. A novel strategy to identify haematology patients at high risk of developing Aspergillosis. Frontiers in Immunology 12, article number: 780160. (10.3389/fimmu.2021.780160)
- Griffiths, J. S. et al. 2021. A human Dectin-2 deficiency associated with invasive aspergillosis. Journal of Infectious Diseases 224(7), pp. 1219-1224. (10.1093/infdis/jiab145)
- Hashem, H. et al. 2021. Hematopoietic cell transplantation cures adenosine deaminase 2 deficiency: report on 30 patients. Journal of Clinical Immunology 41, pp. 1633-1647. (10.1007/s10875-021-01098-0)
- Hernández-Boluda, J. et al. 2021. Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry. American Journal of Hematology 96(10), pp. 1186-1194. (10.1002/ajh.26279)
- Lawless, S. et al. 2021. IgD subtype but not IgM or non-secretory is a prognostic marker for poor survival following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results from the EBMT CALM (Collaboration to collect Autologous Transplant Outcomes in Lymphomas and Myeloma) study. Clinical Lymphoma, Myeloma and Leukemia 21(10), pp. 686-693. (10.1016/j.clml.2021.05.012)
- Craddock, C. et al. 2021. Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia. Journal of Clinical Oncology 39(7), pp. 768-778. (10.1200/JCO.20.02308)
2020
- Anthias, C. et al. 2020. Reducing the diversity of allogeneic transplant protocols in the UK through a BSBMT Anthony Nolan Protocol Harmonization Initiative. Bone Marrow Transplantation 55(9), pp. 1840–1843. (10.1038/s41409-020-0870-0)
- Wright, R. et al. 2020. Quality of life following allogeneic stem cell transplantation for patients age >60 years with acute myelogenous leukemia. Biology of Blood and Marrow Transplantation 26(8), pp. 1527-1533. (10.1016/j.bbmt.2020.04.020)
2018
- Hartono, S. P., Vargas-Hernández, A., Ponsford, M. J., Chinn, I. K., Jolles, S., Wilson, K. and Forbes, L. R. 2018. Novel STAT1 gain-of-function mutation presenting as combined immunodeficiency. Journal of Clinical Immunology 38(7), pp. 753-756. (10.1007/s10875-018-0554-3)
- Sahebi, F. et al. 2018. Incidence of second primary malignancies after autologous transplantation for multiple myeloma in the era of novel agents. Biology of Blood and Marrow Transplantation 24(5), pp. 930-936. (10.1016/j.bbmt.2018.01.006)
- Douglas, K. W. et al. 2018. UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy. Journal of Clinical Apheresis 33(1), pp. 46-59. (10.1002/jca.21563)
- Mahdi, A. J. et al. 2018. Successful molecular targeted treatment of AML in pregnancy with Azacitidine and Sorafenib with no adverse fetal outcomes. British Journal of Haematology 180(4), pp. 603-604. (10.1111/bjh.14417)
2017
- Hashem, H. et al. 2017. Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2. Blood 130(24), pp. 2682-2688. (10.1182/blood-2017-07-798660)
2015
- Parrish, C. et al. 2015. Autologous stem cell transplantation is an effective salvage therapy for primary refractory multiple myeloma. Biology of Blood and Marrow Transplantation 21(7), pp. 1330-1334. (10.1016/j.bbmt.2015.03.026)
2014
- Dharmagunawardena, R. et al. 2014. A retrospective multi-centre study of the effects of allogeneic haematopoietic SCT on pulmonary function. Bone Marrow Transplantation 49, pp. 1442-1443. (10.1038/bmt.2014.154)
2009
- Hewamana, S., Austen, B., Murray, J., Johnson, S. and Wilson, K. 2009. Intestinal perforation secondary to haematopoietic stem cell transplant associated thrombotic microangiopathy. European Journal of Haematology 83(3), pp. 277-277. (10.1111/j.1600-0609.2009.01267.x)
2006
- Dasgupta, R. K. et al. 2006. Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect. Bone Marrow Transplantation -Basingstoke then London- 37(5), pp. 455-461. (10.1038/sj.bmt.1705271)
- Cavill, I. et al. 2006. Iron and the anaemia of chronic disease: a review and strategic recommendations. Current Medical Research and Opinion 22(4), pp. 731-737. (10.1185/030079906X100096)
2005
- Gupta, V. et al. 2005. A third course of anti-thymocyte globulin in aplastic anaemia is only beneficial in previous responders. British Journal of Haematology 129(1), pp. 110-117. (10.1111/j.1365-2141.2005.05406.x)
- Navabi, H. et al. 2005. Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial. Blood Cells, Molecules, and Diseases 35(2), pp. 149-152. (10.1016/j.bcmd.2005.06.008)
Erthyglau
- Loke, J. et al. 2023. Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS. Blood Advances 7(14), pp. 3666-3676. (10.1182/bloodadvances.2022009493)
- Ljungman, P. et al. 2023. Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry. Frontiers in Immunology 14, article number: 1125824. (10.3389/fimmu.2023.1125824)
- Drozd-Sokołowska, J. et al. 2022. Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation-study on behalf of CMWP of the EBMT. Bone Marrow Transplantation 57, pp. 633-640. (10.1038/s41409-022-01592-y)
- Hashem, H. et al. 2022. Correction to: Hematopoietic cell transplantation cures adenosine deaminase 2 deficiency: report on 30 patients. Journal of Clinical Immunology (10.1007/s10875-022-01280-y)
- Gutiérrez-García, G. et al. 2022. Long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high-risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party-EBMT. British Journal of Haematology 196(4), pp. 1018-1030. (10.1111/bjh.17939)
- Griffiths, J. S. et al. 2021. A novel strategy to identify haematology patients at high risk of developing Aspergillosis. Frontiers in Immunology 12, article number: 780160. (10.3389/fimmu.2021.780160)
- Griffiths, J. S. et al. 2021. A human Dectin-2 deficiency associated with invasive aspergillosis. Journal of Infectious Diseases 224(7), pp. 1219-1224. (10.1093/infdis/jiab145)
- Hashem, H. et al. 2021. Hematopoietic cell transplantation cures adenosine deaminase 2 deficiency: report on 30 patients. Journal of Clinical Immunology 41, pp. 1633-1647. (10.1007/s10875-021-01098-0)
- Hernández-Boluda, J. et al. 2021. Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry. American Journal of Hematology 96(10), pp. 1186-1194. (10.1002/ajh.26279)
- Lawless, S. et al. 2021. IgD subtype but not IgM or non-secretory is a prognostic marker for poor survival following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results from the EBMT CALM (Collaboration to collect Autologous Transplant Outcomes in Lymphomas and Myeloma) study. Clinical Lymphoma, Myeloma and Leukemia 21(10), pp. 686-693. (10.1016/j.clml.2021.05.012)
- Craddock, C. et al. 2021. Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia. Journal of Clinical Oncology 39(7), pp. 768-778. (10.1200/JCO.20.02308)
- Anthias, C. et al. 2020. Reducing the diversity of allogeneic transplant protocols in the UK through a BSBMT Anthony Nolan Protocol Harmonization Initiative. Bone Marrow Transplantation 55(9), pp. 1840–1843. (10.1038/s41409-020-0870-0)
- Wright, R. et al. 2020. Quality of life following allogeneic stem cell transplantation for patients age >60 years with acute myelogenous leukemia. Biology of Blood and Marrow Transplantation 26(8), pp. 1527-1533. (10.1016/j.bbmt.2020.04.020)
- Hartono, S. P., Vargas-Hernández, A., Ponsford, M. J., Chinn, I. K., Jolles, S., Wilson, K. and Forbes, L. R. 2018. Novel STAT1 gain-of-function mutation presenting as combined immunodeficiency. Journal of Clinical Immunology 38(7), pp. 753-756. (10.1007/s10875-018-0554-3)
- Sahebi, F. et al. 2018. Incidence of second primary malignancies after autologous transplantation for multiple myeloma in the era of novel agents. Biology of Blood and Marrow Transplantation 24(5), pp. 930-936. (10.1016/j.bbmt.2018.01.006)
- Douglas, K. W. et al. 2018. UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy. Journal of Clinical Apheresis 33(1), pp. 46-59. (10.1002/jca.21563)
- Mahdi, A. J. et al. 2018. Successful molecular targeted treatment of AML in pregnancy with Azacitidine and Sorafenib with no adverse fetal outcomes. British Journal of Haematology 180(4), pp. 603-604. (10.1111/bjh.14417)
- Hashem, H. et al. 2017. Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2. Blood 130(24), pp. 2682-2688. (10.1182/blood-2017-07-798660)
- Parrish, C. et al. 2015. Autologous stem cell transplantation is an effective salvage therapy for primary refractory multiple myeloma. Biology of Blood and Marrow Transplantation 21(7), pp. 1330-1334. (10.1016/j.bbmt.2015.03.026)
- Dharmagunawardena, R. et al. 2014. A retrospective multi-centre study of the effects of allogeneic haematopoietic SCT on pulmonary function. Bone Marrow Transplantation 49, pp. 1442-1443. (10.1038/bmt.2014.154)
- Hewamana, S., Austen, B., Murray, J., Johnson, S. and Wilson, K. 2009. Intestinal perforation secondary to haematopoietic stem cell transplant associated thrombotic microangiopathy. European Journal of Haematology 83(3), pp. 277-277. (10.1111/j.1600-0609.2009.01267.x)
- Dasgupta, R. K. et al. 2006. Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect. Bone Marrow Transplantation -Basingstoke then London- 37(5), pp. 455-461. (10.1038/sj.bmt.1705271)
- Cavill, I. et al. 2006. Iron and the anaemia of chronic disease: a review and strategic recommendations. Current Medical Research and Opinion 22(4), pp. 731-737. (10.1185/030079906X100096)
- Gupta, V. et al. 2005. A third course of anti-thymocyte globulin in aplastic anaemia is only beneficial in previous responders. British Journal of Haematology 129(1), pp. 110-117. (10.1111/j.1365-2141.2005.05406.x)
- Navabi, H. et al. 2005. Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial. Blood Cells, Molecules, and Diseases 35(2), pp. 149-152. (10.1016/j.bcmd.2005.06.008)